Z.ai's shares rose after the company launched a new AI model that it claimed runs only on Chinese ch

ZLAB has grown from a Greater China licensing platform into a dual-engine biopharma. They have a gro

SHANGHAI & CAMBRIDGE, Mass. & AMSTERDAM--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688)

Zai Lab NASDAQ: ZLAB said its second-quarter net product revenue rose 11% sequentially to $105.8 mil

Citigroup analyst Yigal Nochomovitz maintains Zai Lab (NASDAQ:ZLAB) with a Buy and raises the pri

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the q

Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.46) per share which missed the analyst consen

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today annou

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ: ZLAB - Get Free Report) have earned an average ra

- NECs are aggressive malignancies with poor prognoses and limited treatment options, representing s

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today annou

Zai Lab (NASDAQ: ZLAB - Get Free Report) and Viridian Therapeutics (NASDAQ: VRDN - Get Free Report)

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today annou

- European Medicines Agency's Committee for Orphan Medicinal Products recognized zoci's prel

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today annou

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today annou

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today annou

U.S. stock futures were lower this morning, with the Nasdaq futures falling around 100 points on Mon

Zai Lab faces stalling growth in Greater China due to price controls and declining Zejula revenues,

Zai Lab reported promising preliminary data from an ongoing registration-enabling multicenter, Phase

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today annou

Zai Lab NASDAQ: ZLAB reported a year-over-year decline in first-quarter 2026 product revenue as pres

Citigroup analyst Yigal Nochomovitz maintains Zai Lab (NASDAQ:ZLAB) with a Buy and lowers the pri

Zai Lab Limited (ZLAB) Q1 2026 Earnings Call Transcript

Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed i

Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.46) per share which beat the analyst consensu

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today annou

 Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed i

Boehringer Ingelheim and Zai Lab (NASDAQ:ZLAB, HKEX: 9688))) today announced a clinical collaboratio

Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced a global clinical trial collaboration wi

JP Morgan analyst Anupam Rama maintains Zai Lab (NASDAQ:ZLAB) with a Overweight and lowers the pr

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced three of the Company's internally-dev

Cantor Fitzgerald analyst Li Watsek maintains Zai Lab (NASDAQ:ZLAB) with a Overweight and lowers

Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.46) per share which missed the analyst consen

JP Morgan analyst Anupam Rama maintains Zai Lab (NASDAQ:ZLAB) with a Overweight and lowers the pr

- Zocilurtatug pelitecan (Zoci) positioned to become Zai Lab's first global oncology launch, wit

UBS analyst Michael Yee initiates coverage on Zai Lab (NASDAQ:ZLAB) with a Buy rating and announc

Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that China's National Medical Produc

Reviva Pharmaceuticals said the FDA recommended a second Phase 3 trial for its schizophrenia drug br

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Product

Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced the dosing of the first participant in a

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced updated data from the global Phase 1 clin

- Oral presentation to feature new data highlighting the potential of zocilurtatug pelitecan (former